Table 3.
Maternal pregnancy and birth outcomes of pregnancies exposed to newer ASMs.
| All newer ASMs* | BRV | ESL | LCM | ZSN | |
|---|---|---|---|---|---|
| Exposed pregnancies (n,%) | 34 (100) | 8 (23) | 8 (23) | 6 (17) | 12 (34) |
| Pregnancy outcome (n, %) | |||||
| Livebirth | 28 (82) | 6 (75) | 6 (75) | 5 (83) | 11 (92) |
| Spontaneous miscarriage | 6(18) | 2 (25) | 2 (25) | 1 (17) | 1 (8) |
| Gestation at birth in weeksa (median, min–max) |
39 (27–41) | 39 (27–40) | 39 (37–41) | 38 (34–39) | 39 (36–40) |
| Onset of laboura (n, %) | |||||
| Spontaneous | 9 (32) | 1 (17) | 0 | 3 (60) | 5 (46) |
| Induced | 6 (21) | 1 (17) | 1 (17) | 0 | 3 (27) |
| Pre-labour LSCS | 13 (46) | 4 (66) | 5 (83) | 2 (40) | 3 (27) |
| Mode of deliverya (n, %) | |||||
| SVD/OVD | 12 (43) | 2 (33) | 0 | 3 (60) | 6 (55) |
| LSCS | 16 (57) | 4 (66) | 6 (100) | 2 (40) | 5 (46) |
| Pregnancy complicationsb | |||||
| GDM | 4 (12) | 2 (25) | 0 | 1 (17) | 1 (8) |
| Antepartum bleeding | 4 (12) | 0 | 2 (25) | 0 | 2 (17) |
| Infection | 5 (15) | 0 | 2 (25) | 1 (17) | 2 (17) |
| Otherc | 4 (12) | 2 (25) | 1 (13) | 1 (17) | 0 |
| No. of antenatal patient encountersa (median, [IQR]) | 22 [13] | 23 [6] | 19 [3] | 24 [9] | 22 [8] |
| Maternal LOS at delivery in daysa (median, [IQR]) | 3 [3] | 3 [3] | 5 [4] | 4 [2] | 2 [2] |
Abbreviations: ASM – antiseizure medicine, BRV – brivaracetam, ESL – eslicarbazepine, GDM – gestational diabetes mellitus, LCM – lacosamide, ZSN – zonisamide, IQR – interquartile range, SVD – spontaneous vaginal delivery, OVD – operative vaginal delivery, LSCS – lower segment caesarean section, LOS – length of stay.
Totals column (All newer ASMs) includes 1 perampanel exposure; 1 pregnancy was exposed to both eslicarbazepine and zonisamide (included in individual columns), but is counted as a single pregnancy in the totals column.
Excludes spontaneous miscarriages.
Women could contribute > 1 pregnancy complication.
Severe hyperemesis gravidarum, severe anaemia, or substance misuse.